Oxidien Pharmaceuticals Announce Addition to Scientific and Medical Advisory Board
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, announced three additions to its Scientific and Medical Advisory Board (SMAB) to provide external advice on its development activities and clinical program in secondary hyperoxaluria. Helena Cowley,... Read More